Incidence and predictors of tuberculosis among children receiving antiretroviral therapy in the Wolaita Zone: A retrospective cohort study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
12
2022
accepted:
31
08
2023
medline:
25
9
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
epublish
Résumé
Tuberculosis is the leading cause of morbidity and mortality among children living with the human immunodeficiency virus (HIV), mainly in sub-Saharan Africa, including Ethiopia. Tuberculosis remains a significant health concern for HIV-positive children in Ethiopia. There is a paucity of data on the incidence and predictors of tuberculosis among children living with HIV on antiretroviral therapy in the Wolaita zone. Hence, this study aimed to assess the incidence and predictors of tuberculosis among children living with HIV on antiretroviral therapy in the Wolaita zone between January 2010 to December 2020. A retrospective cohort study was conducted among 389 children receiving antiretroviral therapy in Wolaita zone health facilities between January 2010 to December 2020. The checklist was adapted from the standardized antiretroviral treatment (ART) follow-up form currently used by the institutions' ART clinics. The Kaplan-Meier survival function and Log-rank were used to estimate the survival for each categorical variable to compare the survival between different exposure groups. Both bivariable and multivariable parametric survival Gompertz models were fitted to identify predictors of tuberculosis among HIV-positive children. The association was summarized using an adjusted hazard ratio (AHR), and statistical significance was declared at 95% CI and p-value < 0.05. The goodness of the model fit was assessed using a Cox-Snell residual plot. The incidence rate of tuberculosis among children living with HIV was 3.5 (95% CI 2.7-4.5) per 100 child years. World Health Organization clinical stage III or IV (AHR = 2.31, 95% CI [1.26, 4.22]), hemoglobin level <10 g/dL (AHR = 2.87, 95% CI [1.51, 5.45]), fair or poor ART adherence (AHR = 4.4, 95% CI[2.18, 9.05]), underweight (AHR = 2.55, 95% CI [1.45, 4.51]), age >10 years (AHR = 3.62; 95% CI [1.29, 10.0]), and cotrimoxazole preventive therapy (AHR = 0.23; 95% CI [0.08, 0.60]) were among the independent predictors of TB occurrence. The incidence of tuberculosis among children on ART was high. HIV-positive children presenting with advanced disease staging (III and IV), anemia, "fair" and "poor" ART adherence, underweight, age above ten years, and not receiving cotrimoxazole preventive therapy were at higher risk of TB. Therefore, counseling on ART adherence, early diagnosis, and prompt treatment of anemia and malnutrition are recommended to avert tuberculosis.
Sections du résumé
BACKGROUND
Tuberculosis is the leading cause of morbidity and mortality among children living with the human immunodeficiency virus (HIV), mainly in sub-Saharan Africa, including Ethiopia. Tuberculosis remains a significant health concern for HIV-positive children in Ethiopia. There is a paucity of data on the incidence and predictors of tuberculosis among children living with HIV on antiretroviral therapy in the Wolaita zone. Hence, this study aimed to assess the incidence and predictors of tuberculosis among children living with HIV on antiretroviral therapy in the Wolaita zone between January 2010 to December 2020.
METHODS
A retrospective cohort study was conducted among 389 children receiving antiretroviral therapy in Wolaita zone health facilities between January 2010 to December 2020. The checklist was adapted from the standardized antiretroviral treatment (ART) follow-up form currently used by the institutions' ART clinics. The Kaplan-Meier survival function and Log-rank were used to estimate the survival for each categorical variable to compare the survival between different exposure groups. Both bivariable and multivariable parametric survival Gompertz models were fitted to identify predictors of tuberculosis among HIV-positive children. The association was summarized using an adjusted hazard ratio (AHR), and statistical significance was declared at 95% CI and p-value < 0.05. The goodness of the model fit was assessed using a Cox-Snell residual plot.
RESULTS
The incidence rate of tuberculosis among children living with HIV was 3.5 (95% CI 2.7-4.5) per 100 child years. World Health Organization clinical stage III or IV (AHR = 2.31, 95% CI [1.26, 4.22]), hemoglobin level <10 g/dL (AHR = 2.87, 95% CI [1.51, 5.45]), fair or poor ART adherence (AHR = 4.4, 95% CI[2.18, 9.05]), underweight (AHR = 2.55, 95% CI [1.45, 4.51]), age >10 years (AHR = 3.62; 95% CI [1.29, 10.0]), and cotrimoxazole preventive therapy (AHR = 0.23; 95% CI [0.08, 0.60]) were among the independent predictors of TB occurrence.
CONCLUSION
The incidence of tuberculosis among children on ART was high. HIV-positive children presenting with advanced disease staging (III and IV), anemia, "fair" and "poor" ART adherence, underweight, age above ten years, and not receiving cotrimoxazole preventive therapy were at higher risk of TB. Therefore, counseling on ART adherence, early diagnosis, and prompt treatment of anemia and malnutrition are recommended to avert tuberculosis.
Identifiants
pubmed: 37733689
doi: 10.1371/journal.pone.0291502
pii: PONE-D-22-34007
pmc: PMC10513190
doi:
Substances chimiques
Trimethoprim, Sulfamethoxazole Drug Combination
8064-90-2
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0291502Informations de copyright
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
N Am J Med Sci. 2013 Mar;5(3):220-3
pubmed: 23626959
Microorganisms. 2023 Mar 18;11(3):
pubmed: 36985358
Pan Afr Med J. 2014 Jan 17;17:26
pubmed: 24932337
Curr HIV Res. 2018;16(6):436-446
pubmed: 30767743
Ann Intern Med. 2012 Sep 4;157(5):313-24
pubmed: 22944873
PLoS One. 2021 Jun 30;16(6):e0253449
pubmed: 34191846
Life (Basel). 2020 Oct 29;10(11):
pubmed: 33138069
J Trop Med. 2021 Aug 25;2021:9996953
pubmed: 34545289
BMC Res Notes. 2018 Oct 20;11(1):745
pubmed: 30342550
AIDS Res Hum Retroviruses. 2018 Jan;34(1):46-55
pubmed: 28670966
Trop Med Health. 2020 Feb 18;48:7
pubmed: 32099521
Infection. 2016 Jun;44(3):291-9
pubmed: 26471512
Food Nutr Bull. 2010 Dec;31(4):S313-44
pubmed: 21214036
J Pediatric Infect Dis Soc. 2017 Jun 01;6(2):161-167
pubmed: 28204517
Thorax. 2017 Jun;72(6):559-575
pubmed: 28115682
BMC Infect Dis. 2018 Jun 4;18(1):252
pubmed: 29866076
Trans R Soc Trop Med Hyg. 2016 Mar;110(3):148-50
pubmed: 26884490
BMC Infect Dis. 2020 Jan 16;20(1):50
pubmed: 31948393
Cureus. 2022 Aug 7;14(8):e27746
pubmed: 36106202
Front Immunol. 2021 Feb 25;12:634489
pubmed: 33732256
Epidemiol Health. 2019;41:e2019028
pubmed: 31319659
PLoS One. 2016 Apr 12;11(4):e0152941
pubmed: 27070435
Int Sch Res Notices. 2015 May 26;2015:307810
pubmed: 27347516
Lung India. 2009 Jan;26(1):9-16
pubmed: 20165588
Ethiop J Health Sci. 2020 Sep;30(5):653-660
pubmed: 33911825
J Mother Child. 2021 Jan 29;23(3):159-162
pubmed: 33759428
BMC Med. 2016 Mar 23;14:50
pubmed: 27004529
J Pediatr Gastroenterol Nutr. 2013 Aug;57(2):258-64
pubmed: 23880630
BMC Infect Dis. 2019 May 10;19(1):405
pubmed: 31077133
AIDS. 2013 May 15;27(8):1273-81
pubmed: 23343909
PLoS One. 2018 May 22;13(5):e0197145
pubmed: 29787596